

State of California—Health and Human Services Agency California Department of Public Health



OFFICE OF AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2017-13

Date: December 22, 2017

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF A NEW HEPATITIS C VIRUS (HCV) MEDICATION TO

THE AIDS DRUG ASSISTANCE PROGRAM (ADAP) FORMULARY AND

REMOVAL OF AN OBSOLETE DRUG

Effective December 22, 2017, glecaprevir/pibrentasvir (Mavyret) has been added to the ADAP formulary. Mavyret, which combines 100 mg of glecaprevir and 40 mgs pibrentasvir received federal Food and Drug Administration approval on August 3, 2017. The new HCV drug was approved for the treatment of HCV infected patients, genotypes 1 through 6 who are without liver cirrhosis or have compensated cirrhosis. This new HCV medication also has the added benefit of being priced well below the cost of other HCV medications currently on the market. The ADAP Medical Advisory Committee (MAC) voted to recommend Mavyret for addition to the formulary on September 27, 2017.

Also **effective December 22, 2017**, ADAP has removed one obsolete drug from its formulary. Nandrolone (Deca-Durabolin), which was originally added to the ADAP formulary on September 11, 1998, is a steroid that was prescribed to combat wasting syndrome in ADAP clients; however, this medication is no longer commercially available in the United States other than as a compounded drug, which is not covered by ADAP.



Management Memorandum 2017-13 Page 2

Because this medication is no longer commercially available, the ADAP MAC voted to recommend the removal of this medication from the ADAP formulary.

If you have any questions regarding these changes to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Sandra Robinson, MBA Chief, ADAP Branch

Sandan Hore

Office of AIDS